Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
The Lancet. Oncology|September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
Cancer Research|October 29, 2021
Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune ResponseNisha Kanwar, Zaldy Balde, Ranju Nair, et al.
Nature Communications|August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityS Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Molecular Therapy. Methods & Clinical Development|June 14, 2024
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patientsTianjiao Wang, Jean-Marc Navenot, Stavros Rafail, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
The New England Journal of Medicine|October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 YearsPaolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
The New England Journal of Medicine|September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Pageof 16